Pharma Disease Insight: Glioma (PowerPoint PPTX)

Yielding an mPFS of 6.9 months and MOS of 14.6 months, the Stupp regimen has been the efficacy yardstick and standard treatment protocol followed for newly diagnosed glioblastoma patients. However, this patient segment will witness substantial changes with the introduction of three new immunotherapeutic agents—dendritic-cell vaccines DCVax-L and ICT-107 and PD-1 inhibitor Opdivo— in the near future

Market growth drivers over the next five years and afterward will be the approval and extension, as well as rapid uptake of, Opdivo in combination with the current standard of care for treatment of all eligible newly diagnosed patients, garnering almost $1 billion total annual sales and a major patient share in all six major pharmaceutical markets we cover by the end of our forecast period. DCVax-L and ICT-107, which are extremely pricey personalized treatments and will face competition from immune checkpoint inhibitors, will experience modest uptake in the first-line setting.

INTRODUCTION
1. Key Findings
2. Market Share of Colorectal Cancer Drug Classes in 2015 and 2025
3. Disease Market SWOT Analysis
ETIOLOGY AND PATHOPHYSIOLOGY
1. Key Findings
2. Expert Insight
3. Disease Overview
4. Disease Pathophysiology
5. Etiology
6. Pathophysiology
KEY PATHWAYS AND DRUG TARGETS
MARKET OUTLOOK
1. Key Findings
2. Expert Insight
3. Market Overview
4. What Factors Are Driving the Market
5. What Factors Are Constraining the Market